Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy.
Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose.
Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza Ò ; Acorda Therapeutics, Inc., Ardsley, NY, USA;
Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.
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NEUROPATHIC PAIN
Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system [1] and affects an estimated 8% of the general population [2] , leading to severe impairment and reduction of health-related quality of life. [4] . Another family of voltage-gated ion channels that has a crucial role in neuropathic pain is the transient receptor potential (TRP) family. The TRP channels regulate action potential firing frequencies by gating neuronal transmembrane ion influx and modulate the sensitivity of afferent somatosensory neurons [5] . Another factor inducing and maintaining neuropathic pain is the dysfunctional effect and imbalance of algesic and analgesic mediators like cytokines or chemokines during neuro-immune interactions in the peripheral and central nervous system [6] . NaV as well as TRP channels are modulated by these mediators [7, 8] .
So far, the best studied member of the TRP is the transient receptor potential vanilloid 1 (TRPV1) channel [9] . This non-selective cation channel is highly expressed on thinly myelinated A-delta fibers and unmyelinated C fibers (nociceptors) and is in particular permeable to calcium ions. TRPV1 activation typically leads to burning pain sensation and heat hyperalgesia [9] . Numerous TRPV1 activators are known to date that include high temperatures ([42°C), acidic pH, and the pungent ingredient of hot chili peppers, capsaicin, which is a natural ligand of TRPV1 and makes this channel a delicate candidate for pain research.
CURRENT PHARMACOLOGICAL TREATMENTS OF NEUROPATHIC PAIN AND UNMET NEEDS
Treatment of neuropathic pain follows national [10, 11] and international guidelines [12, 13] that broadly overlap with regard to recommendations. In most guidelines, firstline therapy is the use of oral drugs such as tricyclic antidepressants (e.g., amitriptyline), anticonvulsants including calcium channel blockers (e.g., gabapentin, pregabalin), and selective serotonin and noradrenalin reuptake inhibitors (e.g., duloxetine). In the case of localized pain, topical lidocaine can be applied as well as capsaicin cream or patch. If patients do not respond or have mixed pain (i.e., neuropathic pain plus nociceptive pain) the use of opioids can be considered [10] .
Oral medication is used by the majority of patients suffering from neuropathic pain; however, only one-third of these patients seem to achieve satisfying pain relief [14] . Thus, the main problem with oral drugs is the lack of efficacy in a large proportion of patients even after intake of a sufficient dosage, changing to alternative drugs, and when used in combination. In addition, the occurrence of systemic side effects such as weight gain, xerostomia, dizziness, nausea, or cognitive impairment hampers acceptance. The fact that oral medication also needs individual titration and regular intake on a daily basis is an additional limitation reducing flexibility in life, especially for young patients. Drug-drug interactions may also constrain the already limited treatment options, especially in elderly patients with comorbidities. In this context, drug dosage needs to be adapted if renal or hepatic impairment is present. The effect of oral analgesic drugs also starts late; for some drugs an intake period of 6-8 weeks at the maximum dose is needed before drug efficacy can be judged. In localized neuropathic pain states, topically applicable lidocaine and ketamine, as well as low-dose capsaicin cream (0.025-0.075%), are in use. However, these require regular administration and also bear less hazardous but inconvenient disadvantages (e.g., potential contamination of hands during application or clothes afterwards).
Thus, despite a major effort to improve and facilitate oral analgesics there are still several challenges to be taken to meet the needs of patients with neuropathic pain syndromes [15] .
One key obstacle is the lack of knowledge on the precise mechanisms that underlie the different types of neuropathic pain and that drugs are chosen mostly with regard to neuropathic pain in general without differentiation. Neuropathic pain, in general, covers many diverse entities that are of such a different pathophysiological background that a ''one-drug-good-for-all'' approach is condemned to failure. A second problem is that currently available analgesic pharmaceuticals are not exclusively selective for one target. Unselective drug choice (i.e., treating neuropathic pain in general) and molecularly relative unselective drugs (i.e., binding to different targets) are the major reasons that lower drug efficacy and tolerability. Therefore, the transdermal capsaicin 8% patch Qutenza Ò (Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) has been an important addition to the treatment options in neuropathic pain conditions [16] .
HIGH-DOSE CAPSAICIN

Mechanism of Action
Transient receptor potential vanilloid 1 is selectively expressed in nociceptors. The distal endings of cutaneous nociceptors are present in the epidermis and are thus accessible to local treatment. The high-concentration transdermal 8% capsaicin patch Qutenza releases capsaicin into the skin, which can then act on TRPV1 receptors on the nociceptor terminals. This leads to an initial over-excitation of these nerve fibers, which is perceived as burning pain by patients. After this initial excitation, the axons are believed to be ''defunctionalized'', that is, to be less sensitive to external stimuli and also to cease any spontaneous activity that may have been present. Morphologically, intraepidermal nerve fiber endings disappear after capsaicin application, which can be assessed using immunohistochemistry and the panaxonal marker protein gene product (PGP) 9.5 which is routinely used to visualize intraepidermal nerve fibers [17] . In the case of Qutenza, these nerve fiber endings recover after 24 weeks, at least in healthy volunteers [18] .
Investigations in patients with pain states treated with capsaicin have not been performed so far. Thus, several questions remain, such as a potential correlation between fiber density and pain intensity and the phenotype of the regenerating fibers with regard to their channel repertoire. Also, whether this disappearance and recovery of immunostaining for PGP 9.5 reflects true degeneration and regeneration or repressed production of the antigen detected in the immunofluorescence, is as yet unknown.
Another potential mechanism is based on the interaction of TRPV1 with b-tubulin. TRPV1 activation leads to a microtubule disassembly in vitro by direct action and supported by the axonal calcium ion overload via excessive ion influx [19] . Whether Qutenza has a similar effect in vivo remains to be proven.
One apparent paradox is that neuropathic pain states are usually associated with a loss of intraepidermal nociceptor terminals [20, 21] . If these target fibers are gone, where would a TRPV1 agonist bind? The most favored hypothesis in this context is that the remaining nociceptors become hyperactive and hypersensitive on the basis of alterations in TRPV1 channel activity and expression. There is evidence for an increase in TRPV1 channel quantity on inflamed nociceptors [22] and also for the sensitization of these nociceptors by local algesic inflammatory mediators and growth factors [23, 24] .
There In one multicenter, randomized-controlled trial (RCT), 206 patients with PHN were treated with transdermal 8% capsaicin and 42% of them reported a C30% reduction in pain intensity versus 32% in patients treated with the placebo patch [29] . Similar results were reported by others after application of the 8% capsaicin patch in 194 patients [31] . In another RCT, 32 patients with PHN were randomized to be treated with transdermal 8% capsaicin; a decrease in pain intensity ratings of approximately 30% in the verum group compared to the control group was reported [30] . The treatment of 200 patients with PHN with 8% capsaicin patch led to a reduction of the mean percentage of pain ratings that was greater than in the placebo group [32] . In 225 patients with painful HIV-associated neuropathy, transdermal 8% capsaicin led to a reduction in pain ratings in 23% of patients on verum versus 11% of patients on placebo [34] . In another study this effect could not be confirmed [33] .
Taken together one study [33] out of six was negative on the primary outcome with the capsaicin 8% patch, while in the other five studies more patients reported a positive effect when treated with the high-concentration patch compared to the low concentrated patch, as also stated in a recent Cochrane review [35] . Table 1 summarizes the major characteristics of the reported studies [29] [30] [31] [32] [33] [34] .
Particularly when comparing data of the verum (high-dose) and control (low-dose) patch in the reported studies, it is apparent that a low-dose capsaicin patch may also have a notable analgesic effect. In the majority of the studies summarized in Table 1 the difference in analgesic efficacy between the high and the In 2013, an expanded pre-treatment procedure was approved by the European Commission based on the results of a study investigating 122 patients who received either the already approved topical lidocaine pretreatment before Qutenza application or tramadol tablets [36] . Both pre-treatment regimes proved to be equally effective and can now be used in clinical practice.
HOW QUTENZA FITS INTO TREATMENT REGIMENS IN THE REAL WORLD
In clinical practice, patients with neuropathic pain conditions are treated with oral pharmacological drugs as first-line therapy as recommended by national and international guidelines. However, not all patients treated with oral analgesic drugs experience pain relief to a satisfying extent. The consequence is that drug dosage is increased. If this measure also fails to reduce pain, the medication is changed to a drug from a different group, as detailed above, or combination pharmacotherapy is installed. During this mostly exhausting phase of trial and error, the outcome may be biased by decreasing patient compliance. The experience of ineffective drugs with unpleasant adverse effects reduces the motivation of the patient and sometimes may also lead to catastrophizing.
The inconvenience of obligatory daily drug intake is in particular difficult to accept for young and active patients. In this situation, Qutenza may be an alternative for the treating physician and the patient. The novel application and the fact that treatment is episodic are attractive features that are very well accepted by the patients. Qutenza can then be used as monotherapy or in combination with oral analgesic drugs that may, however, be reduced in dosage. This is a good addition to the overall small palette of possibilities for noninterventional pharmaceutical analgesic treatment in neuropathic pain conditions.
Current Experience
Several studies have been published after the approval of Qutenza assessing the efficacy and safety in patients with PHN and HIV-associated painful neuropathy. A meta-analysis including 1,120 patients with PHN and 338 with HIVassociated neuropathy favored Qutenza over the low-dose capsaicin patch when assessing the number of patients with 30% pain reduction as primary outcome [37] . In these trials, overall 44% of the PHN and 41% of the HIV-associated neuropathy patients had a 30% response. Complete pain relief 2-12 weeks after treatment was reported in 11% of patients with PHN and 7% of patients with HIV-associated neuropathy [38] . It took a mean time of 3.4 days for PHN patients and of 6.5 days for HIVneuropathy patients to respond. The mean duration of response after the first Qutenza treatment was 5 months [38] . In the largest non-interventional study so far, QUEPP (Qutenza-safety and effectiveness in peripheral neuropathic pain), the effect of a single Qutenza application was assessed over a period of 3 months in 1,044 patients with neuropathic pain other than of diabetic origin [39] . The authors reported that 43% of patients had 30% pain relief and 24% experienced 50% pain relief. Also, pain intensity and the frequency of pain attacks declined and additional intake of analgesic drugs was reduced. In this study [39] , pre-treatment pain duration was negatively correlated to the effectiveness of Qutenza; however, there have been conflicting data depending on pain etiology [31, 40, 41] .
Another question is how to determine who are responders and who are non-responders of Qutenza treatment. Efforts have been made to identify predictors of a positive Qutenza response. A post hoc analysis of the clinical trial data showed that efficacy of lidocaine pretreatment and a high pretreatment pain score variability were important predictors [42] .
In a multi-center open study with multivariate analysis, time of disease was a major predictor, with a history of pain of less than 6 months being a positive predictor for a response to Qutenza [41] . In this context, effective lidocaine pretreatment and a higher pre-treatment pain score variability were found as potential predictors of good treatment response: older age and longer duration of pre-treatment pain were predictors for poorer outcome after Qutenza treatment [41, 42] . One critical aspect, however, is that a high efficacy of the control patch (0.04%) was also reported [33, 37, 42] .
Qutenza is mostly well tolerated. The major side effects are at site erythema, burning pain, and itch upon patch application that may last for days to weeks [35] . Currently no predictors are known for who will develop patch-pain. Also, no correlation exists so far with regard to patch-pain and analgesic effect of Qutenza. 
SUMMARY AND OUTLOOK
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